Tumor necrosis factor (TNF)-related apoptosis-inducing ligand, or TRAIL, is a promising
anticancer agent as it can induce apoptosis in a wide range of cancers whilst generally …

Recent pre-clinical and clinical studies have shown that stem cell-based therapies hold
tremendous promise for the treatment of human disease. Mesenchymal stem cells (MSC) …

Gliomas are the most aggressive and lethal tumors of the central nervous system, for which
few therapeutic options exist. Surgical resection is the primary treatment for most gliomas; …

Therapeutically engineered stem cells have shown promise for glioblastoma multiforme
(GBM) therapy; however, key preclinical studies are urgently needed for their clinical …

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) possesses strong anti-
cancer potential because of its ability to specifically kill cancer cells. However, clinical use of …

Transdifferentiation (TD) is a recent advancement in somatic cell reprogramming. The direct
conversion of TD eliminates the pluripotent intermediate state to create cells that are ideal …

Mesenchymal stem cell (MSC) has been increasingly applied to cancer therapy because of
its tumor-tropic capability. However, short retention at target tissue and limited payload …

Neural stem cells (NSCs) and mesenchymal stem cells (MSCs) share few characteristics
apart from self-renewal and multipotency. In fact, the neurogenic and osteogenic stem cell …

Engineered neural stem cells (NSCs) are a promising approach to treating glioblastoma
(GBM). The ideal NSC drug carrier for clinical use should be easily isolated and autologous …

The deregulation of the epidermal growth factor receptor (EGFR) has a significant role in the
progression of tumors. Despite the development of a number of EGFR-targeting agents that …